Camilla Jandus

Camilla Jandus, MD, PhD, is Assistant Professor and Head of the “Targeting of cytokine secreting cell group” at the Department of Pathology and Immunology at the University of Geneva, Switzerland. She is also Adjunct Scientist at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland. Camilla Jandus graduated in 2003 from the Faculty of Medicine at the University of Bern, Switzerland, after a training at the Memorial Sloan Kettering Cancer Center in New York. From 2004 to 2008 she performed her MD-PhD training at the Ludwig Institute for Cancer Research in Lausanne. Then, she joined for a 2-year post-doctoral training the Pharmacology Institute in Bern. In 2012, she was appointed Associate Investigator at the Ludwig Center for Cancer Research at the University of Lausanne, where she promoted to SNSF Assistant Professor in 2019. Since 2020 she is tenure-track Assistant Professor at the Department of Pathology and Immunology in Geneva. Dr Jandus main scientific interest is in the study of T cell- and Innate Lymphoid Cell (ILC)- mediated immune responses to human tumors. She has been involved in the immune monitoring of several clinical trials in melanoma patients and was among the first to use peptide-MHC class II multimers to characterize tumor-specific CD4 T cells in patients, directly ex-vivo. She recently identified cytotoxic CD4 T cells in cancer patients and aims at exploiting these cells or their T cell receptors in Phase I clinical trials. In parallel, she is investigating the role of ILC subsets in the context of anti-tumor immunity. She has been pioneering in reporting the pro-tumoral role of ILC2 in human tumors and she is currently developing strategies to target these cells therapeutically in patients.